Skip to content

Clinical trials

Phase 2 Purpura, Thrombocytopenic, Idiopathic trials

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Purpura, Thrombocytopenic, Idiopathic Phase: Phase 2 Clear all

130 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20001
20011
20022
20033
20042
20051
20062
20075
20083
20092
20104
20123
20132
20142
20153
20162
20174
20183
20193
20209
202110
202213
202317
20248
202511
202612

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed43
Unknown status34
Recruiting25
Not yet recruiting8
Withdrawn8
Terminated7
Active, not recruiting5

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Peking University People's Hospital33
Institute of Hematology & Blood Diseases Hospital, China20
Shandong University8
Novartis Pharmaceuticals7
GlaxoSmithKline4
Assistance Publique - Hôpitaux de Paris3
Hospital Universitario Dr. Jose E. Gonzalez3
Weill Medical College of Cornell University3
Amgen2
Eisai Inc.2

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Purpura, Thrombocytopenic, Idiopathic130
Thrombocytopenia10
Hematologic Diseases5
Purpura, Thrombocytopenic4
Purpura, Thrombotic Thrombocytopenic4
Anemia, Hemolytic, Autoimmune3
Blood Platelet Disorders3
Bronchiolitis Obliterans Syndrome3
Purpura3
Autoimmune Diseases2

Trials

Showing 51 to 75 of 130. Each trial links to its page on Pharma Observatory.

30 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.